Recent News
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare, yet aggressive cancer mainly caused by asbestos exposure. There are very limited options for treatment. This is especially true for elderly patients. Conventional therapies might not[…]
Read MoreBlood Biomarkers for Pleural Mesothelioma
A pleural mesothelioma diagnosis is incredibly overwhelming for patients and caregivers. Knowing about treatment options can make it easier on these groups. One area of research is looking at blood-based[…]
Read MoreUsing Precision Cut Tumor Slices to Advance Mesothelioma Treatment
Malignant pleural mesothelioma is a cancer mainly caused by asbestos exposure that is very deadly. Research continues to be done on the cancer, giving hope to patients and their families.[…]
Read MorePleurectomy and Decortication Vs Just Chemotherapy for Mesothelioma
Malignant pleural mesothelioma is a rare and deadly cancer mainly caused by asbestos exposure. It is hard to surgically remove and is very aggressive, which makes it hard to treat.[…]
Read MoreSurgery is Beneficial for Mesothelioma Patients
Pleural mesothelioma is a cancer mainly caused by asbestos exposure. It is a cancer of the pleura, which is a lining of the lungs. The outlook for the disease is[…]
Read MoreArtificial Intelligence and Robotics Improving Mesothelioma Care
Patient care is improving thanks to artificial intelligence and robotics. One country leading the charge in using technology for healthcare is Vietnam. A study from the Cureus Journal of Medical[…]
Read MoreChanges to Staging System for Mesothelioma
Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure. Two very important aspects of treating mesothelioma are classification and staging. They are important because they guide treatment and[…]
Read MorePleural Therapies Can Help Pleural Mesothelioma Patients
Malignant mesothelioma is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs (called the pleura). It is mainly caused by asbestos,[…]
Read MoreA Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects (8479217)
The aims of this Study are to determine:
How much of the Study Drug (bemcentinib) ends up in urine and faeces
How much of the Study Drug and its breakdown products get into the bloodstream
The breakdown products (metabolites) of the Study Drug
The safety of the Study Drug and any side effects that might be associated with it.
Multimodal Therapy Helps Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is an aggressive cancer mainly caused by asbestos exposure. It is a cancer of the mesothelium, which is the lining of certain areas of the body including[…]
Read More